


Product Description
Mometasone Furoate Cream IP 0.1% w/w is a topical corticosteroid used to relieve inflammation, redness, swelling, and itching associated with various inflammatory skin conditions such as dermatitis and psoriasis.
Dermatitis is a common skin disorder characterized by dry, itchy, inflamed skin, while psoriasis is a chronic condition where skin cells multiply rapidly, leading to thickened, scaly, and itchy patches. Mometasone furoate works by suppressing inflammatory responses in the skin, providing relief from discomfort and improving skin appearance.
This cream is intended for short-term use under medical supervision, as prolonged or improper use may lead to skin-related side effects.
Uses
Mometasone Furoate Cream IP 0.1% w/w is used for the treatment of:
-
Inflammatory skin conditions such as dermatitis
-
Psoriasis (excluding widespread or severe plaque psoriasis unless advised)
-
Skin redness, swelling, and itching due to allergic or inflammatory reactions
How it works
Mometasone Furoate is a potent topical corticosteroid that acts within skin cells to:
-
Inhibit the release of inflammatory mediators such as cytokines and prostaglandins
-
Reduce redness, swelling, and itching
-
Suppress exaggerated immune responses triggered by allergens or irritants
By controlling inflammation at the cellular level, it helps restore normal skin function and comfort.
Benefits
-
Effectively reduces inflammation, itching, and redness
-
Provides rapid symptomatic relief in dermatitis and psoriasis
-
Improves skin comfort and appearance
-
Suitable for short-term management of inflammatory skin flare-ups
-
Well tolerated when used as prescribed
How to use
-
For external use only
-
Clean and dry the affected area before application
-
Apply a thin layer of cream once daily or as directed by your doctor
-
Gently rub until absorbed
-
Avoid contact with eyes, mouth, and broken skin
-
Wash your hands before and after use
-
Do not cover the treated area with airtight dressings unless advised
Side Effects
Common side effects, especially with prolonged use, may include:
-
Itching or burning sensation
-
Acne or inflamed hair follicles
-
Thinning of the skin
-
Stinging or tingling sensation at the application site
If side effects persist or worsen, discontinue use and consult your doctor.
Safety Advice
-
Alcohol: No known interaction, but consult your doctor if concerned
-
Pregnancy: Limited data available; use only if benefits outweigh risks
-
Breastfeeding: Use with caution; avoid application on the breast area
-
Children: Use only under medical supervision
-
Avoid long-term use to prevent skin thinning or hormonal effects
-
Do not use on untreated infections unless combined therapy is prescribed
Storage Conditions
-
Store below 30°C (86°F)
-
Protect from light and moisture
-
Keep out of reach of children
FAQs
What is Mometasone Furoate Cream IP 0.1% w/w used for?
It is used to treat inflammatory skin conditions such as dermatitis and psoriasis, helping reduce redness, swelling, and itching.
How does Mometasone Furoate Cream work?
It reduces inflammation by suppressing the release of inflammatory substances inside skin cells.
Can this cream be used for diaper rash?
No. It is not recommended for diaper rash due to increased absorption through delicate infant skin.
Can I use Mometasone Furoate Cream on my face?
Use on the face only if prescribed by your doctor and for a short duration (usually not more than 5 days).
Is it safe for long-term use?
No. Long-term or excessive use may cause skin thinning and other side effects. Always follow your doctor’s instructions.
Manufacturer Name: Daffohils Laboratories Private Limited
Marketed by: First Remedy Pharmacies Private Limited
The information provided on this website is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always consult with a physician or qualified healthcare provider for any medical concerns. Never disregard professional advice or delay seeking it based on the information you read here.

